Month: June 2025

XAI Octagon Floating Rate & Alternative Income Trust Declares its Monthly Common Shares Distribution of $0.070 per Share

Written by Customer Service on June 2, 2025. Posted in Dividend Reports And Estimates.

CHICAGO, June 02, 2025 (GLOBE NEWSWIRE) — XAI Octagon Floating Rate & Alternative Income Trust (the “Trust”) has declared its regular monthly distribution of $0.070 per share on the Trust’s common shares (NYSE: XFLT), payable on July 1, 2025, to common shareholders of record as of June 16, 2025, as noted below. The amount of the distribution represents a 9.09% decrease from the previous month’s distribution amount of $0.077 per share. The Trust’s investment objective is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle. Due to recent market volatility, the loan and CLO asset classes have experienced drastic interest rate spread compression, which has negatively impacted asset class yields. In the most recent quarter, market conditions were marked by heightened...

ABB acquires Bel Products Inc. to expand enclosures portfolio in North America

Written by Customer Service on June 2, 2025. Posted in Mergers And Acquisitions.

ABB acquires Bel Products Inc.Réal Bélanger, President at Bel Products, with Mike Shenouda, Canada Region Leader and General Manager at ABB Installation Products DivisionExtending ABB’s manufacturing capabilities and local production footprint in CanadaABB and Bel Products employeesMontreal, Canada, June 02, 2025 (GLOBE NEWSWIRE) —ABB Electrification Canada Inc. acquires industry-leading enclosures manufacturer Bel Products Inc. Expands ABB’s portfolio in growing enclosures market, serving commercial, industrial, data center and utility customers across Canada and the U.S. Extends ABB’s manufacturing capabilities and local production footprint in CanadaABB Electrification Canada Inc. announced today it has completed its acquisition of Bel Products Inc., a leading Canadian manufacturer of commercial, industrial...

The Ensign Group Adds Skilled Nursing Facility in California

Written by Customer Service on June 2, 2025. Posted in Mergers And Acquisitions.

SAN JUAN CAPISTRANO, Calif., June 02, 2025 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the EnsignTM group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the operations of Toluca Lake Transitional Care, a 52-bed skilled nursing facility located in North Hollywood, California. The real estate will be acquired by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign’s captive real estate company, following receipt of state regulatory approvals. The acquisition was part of the larger acquisition of seven other facilities from Providence Home and Community Care, which was announced in December 2024. The acquisition...

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on June 2, 2025. Posted in Earnings Releases And Operating Results.

Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025 Anticipated Cash Runway Extended into Q4 2026 to Support Key Value-Driving Milestones and Complete the Expansion Study of NUC-7738 EDINBURGH, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. “We have entered 2025 with a clear focus on the advancement of our pipeline through key milestones, into late-stage...

Abivax Presents First Quarter 2025 Financial Results

Written by Customer Service on June 2, 2025. Posted in Public Companies.

Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial results for the quarter ended March 31, 2025. Abivax provided the following updates on its business and operational goals in press releases published:On January 9, 2025 in a press release titled “Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment” On January 23, 2025 in a press release titled “Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025...

Cronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer Conference

Written by Customer Service on June 2, 2025. Posted in Public Companies.

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the TD Cowen 9th Annual Future of the Consumer Conference on Wednesday, June 4, 2025, at 3:30 p.m. EST. A live webcast will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations. About Cronos Group Inc.Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes...

Entertainment Partners to Acquire CASHét Strengthening End-to-End Production Finance Offerings

Written by Customer Service on June 2, 2025. Posted in Mergers And Acquisitions.

BURBANK, Calif., June 02, 2025 (GLOBE NEWSWIRE) — Entertainment Partners (EP), a global leader in entertainment production payroll, finance and management solutions, today announced that it has signed a definitive agreement to acquire CASHét Entertainment, LLC (CASHét), a leading provider of digital payment solutions for the entertainment industry. The acquisition strengthens EP’s commitment to innovation and empowers productions worldwide to operate with greater speed, accuracy and confidence. CASHét offers an industry-leading suite of digital payment services, including its branded Purchasing Card (p-card) and digital AP payments through CASHétPay. In addition, CASHét provides productions with a sophisticated vendor information and bank data verification system that prevents bank and check fraud and saves accounting teams significant...

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

Written by Customer Service on June 2, 2025. Posted in Public Companies.

Media Release COPENHAGEN, Denmark; June 2, 2025New data showed that rinatabart sesutecan (Rina-S®) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response (mDOR) was not reached after a median follow-up of 7.7 months Continued evaluation of single-agent Rina-S 100 mg/m2 in patients with advanced endometrial cancer (EC) is ongoing in the Phase 2 RAINFOL™-01 trial and will be further evaluated in a planned Phase 3 trialGenmab A/S (Nasdaq: GMAB) announced today new data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that with a median on-study follow-up of 7.7 months,...

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

Written by Customer Service on June 2, 2025. Posted in Public Companies.

Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025 BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today will host its inaugural Investor and Analyst Day, featuring presentations from Rapport’s executive team on the Company’s strategic priorities and updates from its clinical pipeline, including progress on the RAP-219 Phase 2a trial in focal epilepsy. The event’s agenda also includes a fireside chat with key opinion leader and professor of Neurology at NYU Langone’s Comprehensive Epilepsy Center,...

Correction: Kvika banki hf.: Transaction in relation to a share buy-back programme

Written by Customer Service on June 2, 2025. Posted in Public Companies.

On Monday 2.6.2025 Kvika announced that post week 22 buy-back Kvika held 157,410,410 of own shares which corresponds to 2.902% of issued shares. However, 157,410,410 of own shares corresponds to 3.34% of issued shares. The revised announcement is as follows: In week 22 Kvika banki hf. („Kvika“ or „the bank“) purchased 23,000,000 of its own shares at the purchase price ISK 380,150,000. See further details below:Date Time No. of shares purchased Share price (rate) Purchase price26.5.2025 10:12:07 1,500,000 15.800 23,700,00026.5.2025 10:53:38 1,000,000 15.925 15,925,00026.5.2025 11:11:52 1,000,000 15.875 15,875,00026.5.2025 13:15:32 1,500,000 15.800 23,700,00026.5.2025 14:17:22 1,000,000 15.800 15,800,00026.5.2025 15:19:12 750,000 15.800 11,850,00027.5.2025 10:18:08 2,000,000 15.975 31,950,00027.5.2025 11:02:06 1,000,000 15.975 15,975,00027.5.2025 12:31:33 1,000,000 15.950 15,950,00027.5.2025 14:09:45 1,500,000 15.900 23,850,00027.5.2025 15:04:50 1,250,000 15.900 19,875,00028.5.2025 10:33:34 2,000,000 17.000 34,000,00028.5.2025 13:21:20 2,000,000 17.350 34,700,00028.5.2025 14:17:08 1,000,000 17.400 17,400,00030.5.2025 10:50:38 2,000,000 17.750 35,500,00030.5.2025 12:10:15 1,500,000 17.700 26,550,00030.5.2025 14:54:22 1,000,000 17.550 17,550,000Total 23,000,000 380,150,000The...

Month: June 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals